CAR T cell News and Research

RSS

Study compares T-cell signaling patterns in two different CAR designs

CAR T-cell therapy, which reprograms immune cells to fight cancer, has shown great promise in people with some blood cancers who have not responded to other treatments. But until now, the underlying biological pathways enabling anti-cancer responses have not been thoroughly examined.

21 Aug 2018

Scientists find two molecules that may combat cancer and chronic infections

To fight viral infections, your immune system calls on CD8 T cells to kill the infected cells. The CD8 T cells can also be used in immunotherapy approaches to kill cancer cells, including the CAR T cell therapy currently attracting broad public attention.

21 Aug 2018

New model of genetically engineered immune cells may help fight solid tumors

Scientists at Memorial Sloan Kettering Cancer Center announced that they have built a new model of genetically engineered immune cells in mice that may allow them to fight solid tumors.

15 Aug 2018

University Hospitals Seidman Cancer Center launches new CAR-T therapy trial

University Hospitals Seidman Cancer Center launched a new clinical trial for CAR-T, joining a select group of hospitals offering the therapy and a smaller group of hospitals manufacturing the CAR-T cells.

14 Aug 2018

New CAR T-cell immunotherapy trial targets solid tumors

Seattle Children's has opened a chimeric antigen receptor (CAR) T-cell immunotherapy trial for children and young adults with relapsed or refractory non-central nervous system EGFR-expressing solid tumors. In the phase 1 trial, STRIvE-01, cancer-fighting CAR T cells will target the EGFR protein expressed in many childhood sarcoma, kidney and neuroblastoma tumors.

7 Aug 2018

Staggering prices slow insurers’ coverage of CAR-T cancer therapy

Patients whose blood cancers have failed to respond to repeated rounds of chemotherapy may be candidates for a new type of gene therapy that could send their cancers into remission for years.

17 Jul 2018

City of Hope receives $3.7 million from CIRM to develop phase 1 glioblastoma trial

The California Institute for Regenerative Medicine board has awarded City of Hope $3.7 million to develop a phase 1 clinical trial for glioblastoma patients that will genetically engineer their stem cells to better tolerate chemotherapy's side effects, allowing them to receive higher doses of the therapy.

30 Jun 2018

Modified natural killer cells may be new player in CAR-T immunotherapies

Emerging CAR-T immunotherapies leverage modified versions of patient's T-cells to target and kill cancer cells.

29 Jun 2018

AbbVie and Calibr collaborate to develop T-cell therapies aimed at cancer

AbbVie , a research-based global biopharmaceutical company, and Calibr, a nonprofit drug discovery division of Scripps Research, today announced a collaboration to develop T-cell therapies aimed primarily at cancer, including solid tumors.

25 Jun 2018

Cureworks collaborative aims to accelerate development of immunotherapies for pediatric cancer

Seattle Children's, with participating members Children's National Health System, BC Children's Hospital and Children's Hospital Los Angeles, has launched CureWorks, an international collaborative of leading academic children's hospitals determined to accelerate the development of immunotherapy treatments for childhood cancer.

12 Jun 2018

MD Anderson and Amgen collaborate to accelerate early-stage oncology therapies

The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies.

1 Jun 2018

Celgene to share new and updated data around novel hematological therapies

Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.

22 May 2018

Obsidian Therapeutics presents preclinical data on regulated IL12 and IL15 programs

Obsidian Therapeutics, Inc., a biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, today announced that the company presented preclinical data on its regulated IL12 and IL15 programs at the Annual Meeting of the American Society of Gene and Cell Therapy in Chicago, IL.

17 May 2018

Cancer Center at BIDMC announces launch of new Immunotherapy Institute

The Cancer Center at Beth Israel Deaconess Medical Center today announced the launch of a new clinical and research institute that will build on BIDMC's long history of leadership in immunotherapy and cell therapeutics.

3 May 2018

New T cell biomarker could be much-needed patient-selection tool for CAR T cell therapy

Penn Medicine researchers may have found the reason why some patients with advanced chronic lymphocytic leukemia don't respond to chimeric antigen receptor T cell therapy, and the answer is tied to how primed patients' immune systems are before the therapy is administered.

30 Apr 2018

New CAR-T therapy could provide safer, more effective cancer treatment

There have been few cancer treatments with such a promising future as using the patient's own immune system.

27 Apr 2018

Gene-editing technology enhances T cell immunotherapies for treating cancer

Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient's own immune cells -- called T cells -- and supercharging them to home in on and attack specific blood cancers, such as hard-to-treat acute lymphoblastic leukemia and non-Hodgkin lymphoma.

6 Mar 2018

Antibiotic use may affect efficacy of cancer immunotherapies

Antibiotic use is known to have a near-immediate impact on our gut microbiota and long-term use may leave us drug-resistant and vulnerable to infection.

2 Mar 2018

Research shows how viruses inactivate immune system, causing cancer

It's no new news that viruses cause cancer. For example, human papillomavirus causes almost all of the more than 500,000 annual worldwide cases of cervical cancer.

2 Mar 2018

New guidelines offer recommendations for assessment, management of immunotherapy side effects

Immunotherapy with immune checkpoint inhibitors is the first of a new generation of immunotherapy treatments, revolutionizing treatment for many different types of cancer. By unleashing the body's immune system to attack cancer, these treatments can send even the most hard-to-treat cancers into lasting remission.

15 Feb 2018